Navigation Links
Investigational drug may increase survival for some patients with advanced melanoma
Date:3/4/2014

An experimental drug aimed at restoring the immune system's ability to spot and attack cancer halted cancer progression or shrank tumors in patients with advanced melanoma, according to a multisite, early-phase clinical trial at Johns Hopkins Kimmel Cancer Center and 11 other institutions. All patients had experienced disease progression despite prior systemic therapies, and most had received two or more prior treatments.

Patients who showed responses to the drug, nivolumab (anti-PD-1; BMS-936558; MDX-1106; ONO-4538), survived for an average 16.8 months following initiation of treatment. Overall, 62 percent of patients (66 of 107) were alive one year following treatment initiation, and 43 percent (46 of 107) were alive two years later. Average survival among 33 patients (31 percent) whose tumors shrank significantly was two years. The drug is now being tested in three larger, phase III trials in melanoma, which generally compare a new therapy with a standard one currently in use.

Results of the study are published online March 3 in the Journal of Clinical Oncology.

"The results seen here are remarkable for these patients with treatment-resistant, advanced metastatic melanoma, who had limited life expectancies when they joined the trial," says study lead-author Suzanne Topalian, M.D., professor of surgery and oncology, and director of the melanoma program at Johns Hopkins.

The immune-based therapy aims not to kill cancer cells directly, but to block a pathway that shields tumor cells from immune system components that are potentially able and poised to fight cancer. The pathway includes two proteins called programmed death-1 (PD-1), expressed on the surface of immune cells, and programmed death ligand-1 (PD-L1), expressed on cancer cells. When PD-1 and PD-L1 join together, they form a biochemical shield protecting tumor cells from being destroyed by the immune system. Another protein involved in the pathway, that is
'/>"/>

Contact: Vanessa Wasta
wasta@jhmi.edu
410-614-2916
Johns Hopkins Medicine
Source:Eurekalert

Page: 1 2

Related medicine news :

1. Investigational drug effective in treating iron deficiency in kidney disease patients on dialysis
2. Investigational Drug Effective in Treating Iron Deficiency in Chronic Kidney Disease Patients on Dialysis: Study
3. NIH launches trial of investigational genital herpes vaccine
4. Investigational PARP inhibitor promising in BRCA-related cancers
5. Targeted investigational therapy potential to overcome crizotinib resistance in lung cancers
6. Investigational malaria vaccine found safe and protective
7. Method patent issued for investigational new class of pain medication
8. Investigational agent targets gene signaling pathways to improve response for patients with CLL
9. Despite recession, childrens health spending increased between 2009-2012, says new report
10. Death of partner associated with increased risk of heart attack, stroke
11. Frequent school moves can increase the risk of psychotic symptoms in early adolescence
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/1/2015)... ... August 01, 2015 , ... “ reTXT ” was featured on NewsWatch ... coolest applications on the market for iOS, Android, and Windows. Joe Toohey, the host ... users to clarify, edit and delete any message including ones already sent. , While ...
(Date:7/31/2015)... ... , ... The Honor Society of Nursing, Sigma Theta Tau International (STTI) convened ... 20-21 July 2015 in San Juan, Puerto Rico. Key nurse leaders from Central and ... Advisor, Nursing and Allied Health Personnel Development, Unit of Human Resources for Health, Department ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... new store run by GoodThreads. The store can be accessed by visiting ... many of which are customizable. The best part: whenever a product is purchased, ...
(Date:7/31/2015)... ... July 31, 2015 , ... Facebook, Twitter, Linkedin and blogs ... social media profiles to better connect with the public. The agency website at ... share insights and opinions. The Rally Insurance Group, Inc.’s pledge to provide effortless ...
(Date:7/31/2015)... ... July 31, 2015 , ... According to an article ... see if they could reach a consensus on the steps that need to be ... the group reached 90 percent consensus on a series of steps that each surgeon ...
Breaking Medicine News(10 mins):Health News:Correct Auto-Correct and Clarify the Unclear with reTXT Messaging App 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 2Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 3Health News:Key Latin American Nurse Leaders Identify Regional Issues During Global Advisory Panel on the Future of Nursing Meeting 4Health News:Mesothelioma Organization Launches New Store 2Health News:Mesothelioma Organization Launches New Store 3Health News:Rally Insurance Group, Inc. Connects to Customers Through Re-branded Social Media Profiles 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 2Health News:Article on Plastic Surgery Consensus Highlights the Duties of Veteran Plastic Surgeons, says Beverly Hills Physicians 3
... , THURSDAY, May 3 (HealthDay News) -- A ... with schizophrenia, cutting patients, risk of relapse by 60 percent. ... also found that schizophrenia patients who take antipsychotics are much ... and have a better quality of life than patients who ...
... jogging increases the life expectancy of men by 6.2 years ... the Copenhagen City Heart study presented at the EuroPRevent2012 meeting. ... hazardous, Peter Schnohr told delegates that the study,s most recent ... hours of jogging per week at a "slow or ...
... eating is motivated by pleasure, rather than hunger, endogenous rewarding ... to a recent study accepted for publication in The Endocrine ... The phenomenon ultimately affects body mass and may be a ... refers to the desire to eat for pleasure, and to ...
... New York, NYThe United States spends more on health care ... superior" care, according to a new study from The Commonwealth ... on health care services, while other countries in the study ... and Switzerland) as much. While the U.S. performs well on ...
... 2D mammography screening results in a 40% reduction in ... a new study shows., The study, conducted at Yale ... 7,578 screening mammograms, found that the recall rate was ... It was 11.1% for 2D screening mammography alone, ...
... with benign breast biopsies do not need follow-up at six months; ... shows. , The study, conducted at Moffitt ... and 24 months. No cancer was found in these patients ... the authors of the study. "Of the 197 follow-up examinations ...
Cached Medicine News:Health News:Antipsychotics Do Help Many With Schizophrenia, Study Finds 2Health News:Antipsychotics Do Help Many With Schizophrenia, Study Finds 3Health News:Regular jogging shows dramatic increase in life expectancy 2Health News:Regular jogging shows dramatic increase in life expectancy 3Health News:Pleasure eating triggers body's reward system and may stimulate overeating 2Health News:US spends far more for health care than 12 industrialized nations, but quality varies 2Health News:US spends far more for health care than 12 industrialized nations, but quality varies 3Health News:US spends far more for health care than 12 industrialized nations, but quality varies 4Health News:Digital breast tomosynthesis cuts recall rates by 40 percent 2
(Date:7/31/2015)... , July 31, 2015 Quietly, ... of experience, the domestic pharmaceutical industry is strong, with ... products to high international standards. One place ... is in sub-Saharan Africa: Morocco has quietly become the ... South Africa . Indeed, Moroccan pharma companies ...
(Date:7/31/2015)... SAN DIEGO , July 31, 2015 /PRNewswire/ ... Co., Ltd. (Headquarters: Tokyo , President ... Therapeutics, Inc. (Headquarters: San Diego, California ... "NASDAQ: HALO") have signed a clinical collaboration agreement to ... "eribulin") in combination with Halozyme,s investigational drug PEGPH20 (PEGylated ...
(Date:7/31/2015)... Magnaquest, a leading Subscription ... cloud computing operators has signed a Proof of ... Internet of Things (IoT) related initiative. The PoC ... model.      (Logo: http://photos.prnewswire.com/prnh/20140807/700645 ) ... business innovations to make healthcare services more accessible ...
Breaking Medicine Technology:PharmaBoardroom Releases New Morocco Pharmaceuticals Report 2PharmaBoardroom Releases New Morocco Pharmaceuticals Report 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 2Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 3Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 4Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 5Eisai and Halozyme Sign Collaboration Agreement to Investigate Eribulin and PEGPH20 in Metastatic Breast Cancer 6Magnaquest Signs a POC With a Leading Pharma Giant in Europe to Manage Subscription Management and Billing for Internet of Things (IoT) 2
... to Destroy,Lung Tumors, WASHINGTON, March 17 ... that "cooks" and kills lung cancer,tumors with ... primary or,metastatic inoperable lung tumors, according to ... Interventional Radiology,s 33rd Annual Scientific Meeting.,Of the ...
... Therapeutics,(Amex: CXM ) and its subsidiary, Tissue ... MATRIX clinical study has been the focus of ... television news,features in Florida, Pennsylvania, Arizona and Southern ... efficacy of Excellarate(TM) for,the potential treatment of non-healing ...
Cached Medicine Technology:Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More 2Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More 3Treatment Gives Lung Cancer Patients With Inoperable Tumors Two Years or More 4Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 2Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 3Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 4Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 5Cardium and Tissue Repair Company's Excellarate Candidate for Healing Diabetic Wounds Gains Media Focus in Multiple Regions Across U.S. 6
... Drawing on over 20 years of ... AquilionTM 16 is at the forefront of ... ability to acquire volumetric data at high ... was created based on extensive clinical experience ...
... IDT 16 is Philips premium 16-slice CT scanner. ... performed to automatically delivering high quality, advanced results, ... in a platform that has been the most ... do comprehensive organ assessment literally within seconds, and ...
... Instruments are designed to facilitate disc removal, ... graft during interbody fusion. The TLIF instruments ... use during TLIF, for which they were ... used very effectively in PLIF and ALIF. ...
... insertion assembly incorporates slotted guides for ... The PathFinder MIS System uses an ... screw insertion assembly incorporates crescent-shaped slotted ... evolutionary Pathfinder MIS pedicle screw system ...
Medicine Products: